"Bringing Hope to Communities Through Tech-Powered Biopharma"
iMetabolic Biopharma functions through the application of its iPlatform™ technology in the development of a First In Class biologic pipeline against a number of key indications.
Although iMBP is still early in its development, it has assembled a seasoned group of clinical, research and business leaders as a formidable team to make our science and business a success.
To help people live longer, healthier and happier lives.
iMetabolic Biopharma Corporation is focused on the deployment of our iPlatform™ technology to develop safe & effective First-In-Class therapeutics that target indications with unmet clinical needs with greater precision to achieve positive patient outcomes
Founder, Chairman & CEO - is a seasoned biotech leader with over 20 years of industry business and research experience. Dr. Kiernan, with successful track records in developing innovation, technology commercializtion and value exit creation, is the lead architect in the development of what has now become iMBP.
Prior to devoting his efforts into iMBP, he honed his entrepreniurial and leadership skills as the Director of Biomarker Discovery at Intrinsic Bioprobes Incorporated and later in Global Business Development at Thermo Fisher Scientific. This evolution in his career has perfectly positioned him to successfully drive iMBP as a company.
Driven By Passion Through Personal Experience
iMBP is a different kind of biopharma company, which begins at the very top.
Recently featured in Top Doctor magazine, Dr. Kiernan is not your typical entrepreneur or biotech visionary.
Having personally experienced the pain, suffering and loss of what disease of a loved one can do to a family, he has never forgotten what matters most….and that is People!
This has rooted iMBP in the commitment and a promise to develop solutions that will give families the chance for "Just One More".
Dr. Stephen A. Munk - Interim - COO and Board Director. Dr. Munk has over 25 years of experience in the life science and pharmaceutical industry. He currently serves as the Deputy Director of the Biodesign Institute at Arizona State University, but spent the last two decades as the CEO of Ash Stevens Inc, a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization. Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances and received six NIH research contacts.
Mr. David F. Hendren - Chief Business Officer. Mr. Hendren has 25+ years of experience in building, funding and launching healthcare, life sciences and bio-medically related companies. He has participated in companies that were able to execute IPO, M&A and licensing exit strategies that have a cumulative total that exceeds over $1 Billion.
Mr. Jeffrey D. Zimmerman, Esq. - General Counsel & Board Secretary. Mr. Zimmerman has over three decades of business law expertise. His legal experience and expertise ranges from direct business advisement through complex merger and acquisitions. He also has extensive experience through his participation on the Boards of several not for profit organizations.
Mr. Nathan Hyland - Dir. Global Business Strategies. Mr. Hyland is a seasoned veteran in international business, corporate leadership and partnership cultivation. His success is guided by living the mantra of courageously embracing new challenges and enjoying the journey so much that the destination is an afterthought!
Mr. André Harrell - CEO; AH2 & Beyond Consulting. With an industrial life science career that spans three decades, Mr. Harrell has worked with many notable Fortune 100 companies such as Johnson & Johnson Inc, Hewlett Packard, BASF, SC Johnson, Bristol Myers Squibb, Mylan Pharmaceutical, Revlon Professional, Twitter, and Novo Nordisk. Through his efforts he has amassed extensive experience in global commercial strategies and corporate development.
Dr. Martin Emanuele - Co-Founder & CEO; Visgenx. With over 30 years of bio-pharmaceutical industry experience; including over two decades in senior executive roles in companies that include CytRx Corp., Avanir Pharmaceuticals and Mast Therapeutics, Dr. Emanuale has experience in developing both research and business teams that have resulted in multiple IND and NDA approvals.
Dr. Gerald I. Shulman - Research Professor. Howard Hughes Medical Institute, Yale University School of Medicine
Dr. Ira J. Goldberg - Division Director. New York University School of Medicine
Dr. Michael R. Briggs - President. Woodland Pharmaceuticals, LLC
Dr. Kirkwood A. Pritchard Jr. - Tenured Professor. Medical College of Wisconsin
Dr. Randall W. Nelson - Research Professor (Retired). Molecular Biosignatures Analysis Unit, Biodesign, ASU
Dr. David Nielsen - Associate Professor. Arizona State University School of Engineering
Dr. Kitt Falk Petersen - Endocrinologist. Yale University School of Medicine
Dr. Damon Dixon - Cardiologist & Lipidologist. Phoenix Children's Hospital
Dr. H. Randall Craig - Endocrinologist (Fertility Specialist). Fertility Treatment Center
Dr. Abhishek Singharoy - Assistant Professor. School of Molecular Sciences and The Biodesign Institute, Arizona State University
Dr. Brent Nannenga - Assistant Professor. School of Engineering and The Biodesign Institute, Arizona State University
Dr. Jeremy Mills - Assistant Professor. School of Molecular Sciences and The Biodesign Institute, Arizona State University